TRDA
Entrada Therapeutics, Inc.
There isn't enough reported data to score TRDA yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
TRDA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
TRDA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
TRDA PE Valuation
TRDA has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
TRDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect TRDA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
TRDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.85 | -$1.36 |
| Q2 2026 | -$3.97 | -$2.19 |
| Q1 2026 | -$4.00 | -594% |
| Q4 2025 | -$3.47 | -282% |
| Q3 2025 | -$2.49 | -251% |
| Q2 2025 | -$1.78 | -159% |
| Q1 2025 | $0.81 | +17% |
| Q4 2024 | $1.91 | +$2.11 |
TRDA lost $3.85 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over TRDA on earnings quality, reporting a profit while its opponent remains loss making.
TRDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $905K | -44% |
| Q2 2026 | $898K | -54% |
| Q1 2026 | $875K | -96% |
| Q4 2025 | $1.3M | -97% |
| Q3 2025 | $1.6M | -92% |
| Q2 2025 | $2M | -98% |
| Q1 2025 | $20.6M | -65% |
| Q4 2024 | $37.4M | -11% |
TRDA's revenue has slid since its 2024 peak: $905,000 last quarter, down 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4607% | -1691 points |
| Q2 2026 | -5007% | -2605 points |
| Q1 2026 | -4835% | -4729 points |
| Q4 2025 | -3249% | -3234 points |
| Q3 2025 | -2915% | -2805 points |
| Q2 2025 | -2403% | -2459 points |
| Q1 2025 | -106% | -142 points |
| Q4 2024 | -16% | -27 points |
TRDA's operating margin was −4607% last quarter, down 1691 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over TRDA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over TRDA on profitability, with a higher operating margin.
TRDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.1M | -$2M |
| Q2 2026 | -$32.5M | -$2.7M |
| Q1 2026 | -$41.7M | -$2.1M |
| Q4 2025 | -$32M | +$244K |
| Q3 2025 | -$28.1M | -$3.2M |
| Q2 2025 | -$29.8M | -177% |
| Q1 2025 | -$39.7M | -$13.3M |
| Q4 2024 | -$32.2M | -$27.3M |
TRDA has burned cash in almost every quarter: −$136M over the past year, against −$130M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over TRDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TRDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +152K shares |
| 1 year | +2.2% | +911K shares |
| 3 years | +22% | +7.6M shares |
| 5 years | +107% | +21.9M shares |
TRDA has 42M diluted shares, up 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over TRDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
TRDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -8.7x | Net Cash |
| Q4 2024 | -2.0x | Net Cash |
| Q3 2024 | -1.3x | Net Cash |
| Q2 2024 | -1.9x | Net Cash |
| Q1 2024 | -2.5x | Net Cash |
TRDA has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
TRDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 20.0 | Neutral |
TRDA's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
TRDA PE vs Healthcare Sector
| Metric | TRDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TRDA has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
TRDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.07 | 2% above |
| 20 week MA | $6.22 | 17% below |
| 50 week MA | $8.73 | 41% below |
| 100 week MA | $8.84 | 42% below |
| 200 week MA | $11.9 | 57% below |
TRDA has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 57% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over TRDA on trend strength, trading above more of its moving averages.
TRDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $17.0 | -29% |
| 2022 | $17.0 | $15.0 | -12% |
| 2023 | $15.0 | $15.1 | +0.8% |
| 2024 | $15.1 | $17.4 | +15% |
| 2025 | $17.4 | $10.4 | -40% |
| 2026 YTD | $10.4 | $5.17 | -50% |
TRDA has finished lower in three of the last five years. It's down 50% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over TRDA on returns for 2026, with the stronger performance.